ABBV

AbbVie is a large-cap biopharma with a durable commercial engine anchored by scale, global distribution, and a broad “growth platform” that has been replacing Humira-era concentration with faster-growing franchises. The near-term moat is strongest in immunology and neuroscience, where AbbVie can bundle deep medical relationships, lifecycle management, and indication expansion to defend share. That said, the business remains exposed to the typical pharma reality that competitive position ultimately depends on ongoing clinical wins and smart deal-making.

Financially, AbbVie exited 2025 with net revenues of about $61.16B (up 8.6%) and adjusted EPS of $10.00, then guided 2026 adjusted EPS to $14.37–$14.57 at the February 4, 2026 report, implying a sharp step-up in earnings power. In early April 2026, management flagged a $744M pre-tax acquired IPR&D and milestones expense tied to Q1 and updated 2026 guidance to reflect that one-time hit, reinforcing that reported earnings can be noisy around business development. Valuation signals are mixed because some screens show a very high P/E, so DIY investors should anchor more on forward earnings power and cash returns; the annualized dividend is about $6.92 per share.

Over the next 12 months, the bull case is continued growth-platform execution plus positive pipeline readouts and/or accretive deals that extend durability beyond current blockbusters. Key risks are additional IPR&D charges (and integration risk) from M&A, slower-than-expected uptake/competition in core growth brands, and policy/pricing pressure that can compress margins. With a low-beta profile, the stock can also lag in risk-on markets if investors rotate away from defensives.

Recommendation: HOLD. AbbVie offers a credible earnings rebound into 2026 and an attractive income profile, but the investment case is partially offset by headline-risk from acquisition accounting and unclear “true” valuation on common data screens.